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The risks of therapeutic misconception and individual patient (n = 1) “trials” in rare diseases such 
as Duchenne dystrophy 
 
There is currently no cure for Duchenne Muscular Dystrophy, but there are some promising 
treatments in development, of which antisense-mediated exon skipping is closest to clinical 
application. The results of the first trials have resulted in significant enthusiasm among 
clinicians, patients, and their parents and attracted widespread attention in both the scientific 
and lay press. Like in many other rare diseases with significant morbidity this fuels the hope 
that at last an effective therapy might be within our reach. Parents, but also some clinicians, are 
now seriously considering treating individual patients with antisense oligonucleotides without 
waiting for proof from well-designed clinical trials that the new therapies are indeed effective 
and safe. 
 
We understand the sense of urgency that is experienced by patients, parents and their 
clinicians, but we hope to explain that the preliminary introduction of incompletely tested drugs 
might lead to dangerous and harmful situations for the patients, endanger the continuation of 
the development of possible effective therapeutic strategies, or even lead to a complete stop in 
the further development of promising drugs. 
 
Exon skipping 
The aim of the exon skipping approach is to restore the disrupted dystrophin reading frame to 
allow the production of Becker-like proteins and potential conversion of the severe Duchenne 
into the milder Becker muscular dystrophy [1]. Exon skipping is achieved using antisense 
oligonucleotides, pieces of modified RNA or DNA, which hybridize to a target exon, hide it from 
the splicing machinery, causing the targeted exon to be “skipped”. A disadvantage of exon 
skipping is its mutation specificity, as different mutations require the skipping of different exons 
to restore the open reading frame [2]. As there is a mutation hotspot, skipping some exons 
applies to larger groups of patients, but even the most applicable exon (exon 51) would benefit 
only 13% of Duchenne patients [2]. Early phase clinical trials for exon 51 skipping show 
encouraging results [1] and trials on exon 44 skipping (applicable to approximately 6% of 
patients) are currently ongoing. Using two different chemistries exon 51 skipping and dystrophin 
restoration could be achieved after systemic administration. However, placebo controlled trials 
to confirm that longer term treatment is effective and safe have not yet been performed. 
 
Nevertheless, requests are made to clinicians for the treatment of individual patients with 
antisense oligonucleotides targeting exon 51, and also additional exons. 
 
The risks of n=1 “trials” 
There is currently no proof that long term treatment with antisense oligonucleotides to induce 
exon skipping is effective and safe. Functional efficacy (beneficial effects on muscle performance 
typically assessed by tests such as the 6 minute walk test) can only be ascertained with placebo 
controlled trials. There are many psychological effects that play a role in trials with children that 
make controlled trials important [3]. In the early phase trials without a placebo, patients know 
they are treated with a potential drug. However, there is probably an additional effect, as the 
children realize their parents know they are treated, and yearn for them to get better. There are 
examples where there seemed to be a functional effect in early phase trials, which could not be 
confirmed in a placebo-controlled trial. Of course we all hope there really will be a functional 
effect after exon skipping treatment, but there is no proof yet. 
 
More importantly, placebo controlled trials are also done to confirm safety of the treatment 
with antisense oligonucleotides. As antisense oligonucleotides are primarily developed for more 
acute diseases, not much is known about longer term tolerability and toxicity of these 
compounds, especially in children and adolescents. Furthermore, the metabolism of Duchenne 
patients is already compromised (e.g. most patients have elevated liver enzymes), making it very 
difficult to monitor safety without a placebo group. In conclusion, at this point in time, we do 
not know yet whether prolonged antisense oligonucleotide treatment is safe in Duchenne 
patients. 
 
Until efficacy and safety are confirmed, it is arguably unethical to treat patients outside of a 
controlled trial setting. The optimal dose and dosing regime have not yet been identified and 
trials have thus far mainly been done in young boys – it is possible that dosing will be different in 
older boys/men who have less muscle. These boys/men have a severe, progressive disease and 
without a placebo group it is impossible to conclude that putative negative effects are due to 
the disease, due to the treatment, due to a combination of the two, or due to an entirely 
different combination of factors. 
 
N=1 trials have been done to test drugs in other diseases [4]. Here, the patient is his/her own 
control and different drugs or a placebo are given over time. This will only work in diseases that 
are very slowly progressive or episodic. In a more progressive disease like Duchenne muscular 
dystrophy, patients will not be back to the baseline state when drug treatment is stopped or 
switched after a number of months. However, the individualized trials as they are requested for 
Duchenne patients will not compare different compounds in one patient, but rather only a 
single compound for an indefinite amount of time. As such, these N=1 trials are not trials in the 
correct sense of the word. Rather they are the administration of potentially dangerous 
substances to a patient in the (possibly unjustified) hope that it might help, but without 
evidence that there are reasonable chances that it will. 
 
Nevertheless, clinicians/scientists are under a lot of stress from parents to start these individual 
“trials”. Giving in creates a serious risk of setting the entire field back should anything go wrong. 
This would extend to the future possibilities for the specific child in the n=1 trial. Clearly with 
Duchenne being a progressive disease, time is of the essence. However, this does not make it all 
right to start treatment with any compound before it is confirmed to be safe and effective. For 
the same reasons, parent and patients cannot invoke “compassionate use” to receive treatment 
with antisense oligonucleotides, as no conclusive proof has been obtained yet that the 
treatment will work at longer term with acceptable safety. Even if the individual boys/men 
agree and accept the risks involved for themselves, the whole field will be set back should 
something go wrong. This means that if single patients say they accept the risks involved in 
doing individualized “trials”, both the clinicians and patients involved in these trials accept the 
risk of delaying (or in the worst case even stopping) the development of a potential treatment 
for all patients worldwide. For example, young men with Duchenne are at risk from sudden 
cardiac death. If such an unfortunate event were to occur in a single patient “trial” it would be 
impossible to know whether the drug might have contributed to this and it might cause alarm 
for the rest of the field. Experimental drugs used in trials have to undergo extensive testing and 
regulatory review to ensure adequate quality standards are met before being given to human 
subjects. In addition, regulatory authorities and ethics committees need to be reassured that 
adequate monitoring procedures are in place before trials can start. Increasingly this means the 
use of an independent monitoring board to regularly review the ongoing safety of the subject in 
context of the whole trial. These measures help to ensure the safety of trial subjects. 
We realize clinicians considering these trials are passionate about helping patients. We want to 
stress though, that treating patients with something that might not be effective or safe is not 
“helping” patients. 
 
Therapeutic misconception 
The requests for exon skipping treatment for individual patients arise from therapeutic 
misconception. Parents and clinicians considering these “trials” think sufficient evidence has 
accumulated to support the treatment of their sons or patients without further testing. 
Unfortunately, this is not the case. Data on new therapeutic approaches and clinical trials should 
be seen in the right context. However, due to the need to obtain funding and publish results in 
an increasingly competitive environment, regrettably the terminology used by scientists in the 
field of applied science tends to oversell findings in cell and animal models in scientific journals 
and conferences [5]. While their fellow researchers are generally aware of the limitations of the 
experimental approaches used, this may be more difficult for patients and their families. We 
should realize that in current times, the patient/parent community of rare diseases is well 
informed and publications about orphan drugs currently being developed are read by all. 
Therefore, the entire field (researchers, clinicians and patient advocacy groups) should take 
responsibility to prevent raising false hope and unrealistic expectations. Obviously, by agreeing 
to conduct trials in single patients, clinicians only increase misconception and also – should exon 
skipping fail to work as hoped – increase the sense of loss and disappointment. 
 
We should all realize it is important, especially when interacting with patients and parents to 
stress the limitations of studies done in cell models (very easy to treat cells, only a proof of 
concept), animal models (we are not mice -or dogs- and mice have a different disease than 
humans) and early phase clinical trials (no placebo group). There is a significant gap between 
studies done in model systems and studies done in patients, and also between early phase 
clinical trials and placebo controlled trials. It is also important to communicate more clearly 
about what exon skipping hopefully can do (slow down disease progression) and what it may 
not be able to do (bring back lost muscle function). In this, word choice is extremely important. 
Using words like “medicine”, “cure” or “treatment” based on experiments done in cells or 
animals, can aberrantly give people the impression there is a real medicine rather than an 
“experimental drug compound”. 
 
We should also realize that many patients and parents perceive a clinical trial as a form of 
treatment, rather than an experiment done in humans to test whether a potential drug is 
effective and safe. Indeed, at times this is even unknowingly stimulated by the caution of 
approval bodies, who in some countries allow testing in minors only when a therapeutic effect is 
expected. Nevertheless, there is a possibility that the tested compound is not effective or safe, 
and until this has been assessed in a placebo controlled trial, one should not treat patients 
outside the trial setting with this compound. 
 
The problem of personalized medicine and individualized drug development 
The exon skipping approach applies to only subsets of patients and the current development 
focuses on those exons that would benefit larger groups of patients. In theory exon skipping 
could be applicable to up to 80% of all patients, but this would require the development of 
antisense oligonucleotides for over 50 different exons. A dialogue with regulatory agencies to 
facilitate the development of additional antisense oligonucleotides has been initiated [6]. 
Antisense oligonucleotides of the same chemistry may eventually be seen as a class, which 
would facilitate access to new antisense oligonucleotides considerably. Still, some tests to 
optimize the antisense oligonucleotides and assess their safety will have to be done. More 
importantly, before considering whether this as an option, regulatory agencies need 
confirmation for two or more exon skipping compounds (with the same backbone) that they are 
safe, effective and act in a similar manner (pharmacokinetic and pharmacodynamic properties) 
[6]. There are requests to develop antisense oligonucleotides to be tested in individualized 
“trials”. However, it will take at least 2-3 years to conduct the pivotal studies for exon 51 
skipping, which are currently being planned. Therefore it is too early for trials of antisense 
oligonucleotides applicable to smaller groups of patients. What one should also realize is that 
these trials (should they ever take place) will involve small groups of patients and not single 
patients. Finally, aside from the safety and ethical aspects and the risks involved, clinicians 
considering “treatment” of single patients outside a trial setting should be aware of the practical 
aspects. Acquiring enough of the compound (antisense oligonucleotides in this case) at a clinical 
grade will be expensive, especially taking into account that patients will need lifelong treatment. 
In summary, we understand the urgency of patients, parents and their clinicians, but hope we to 
have explained that the whole field benefits only from well conducted trials to confirm safety 
and efficacy and that individual trials with drugs for which we have insufficient data on safety 
and efficacy should not be done. 
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